NYSE:TEVAPharmaceuticals
Teva (TEVA) Secures Revolver Extension: A Subtle Shift In Balance Sheet Risk Or Strategy?
In December 2025, Teva Pharmaceutical Industries obtained lender consent to extend the maturity of its senior unsecured sustainability-linked revolving credit facility from April 29, 2027, to April 29, 2028, while resetting key leverage and interest-cover covenants tied to potential Investment Grade Status.
This covenant flexibility, together with recent progress in higher-margin branded and biosimilar products, gives Teva more room to align its balance sheet with its ongoing business...